Advertisement

Cell and Tissue Research

, Volume 346, Issue 3, pp 393–405 | Cite as

Nesfatin-1 stimulates glucagon and insulin secretion and beta cell NUCB2 is reduced in human type 2 diabetic subjects

  • Matteo Riva
  • Marloes Dekker Nitert
  • Ulrikke Voss
  • Ramasri Sathanoori
  • Andreas Lindqvist
  • Charlotte Ling
  • Nils WierupEmail author
Regular Article

Abstract

Nesfatin-1 is a novel anorexigenic regulatory peptide. The peptide is the N-terminal part of nucleobindin 2 (NUCB2) and is expressed in brain areas regulating feeding. Outside the brain, nesfatin-1 expression has been reported in adipocytes, gastric endocrine cells and islet cells. We studied NUCB2 expression in human and rodent islets using immunocytochemistry, in situ hybridization and western blot. Furthermore, we investigated the potential influence of nesfatin-1 on secretion of insulin and glucagon in vitro and in vivo in mice and in INS-1 (832/13) cells. The impact of type 2 diabetes (T2D) and glucolipotoxicity on NUCB2 gene expression in human islets and its relationship to insulin secretory capacity and islet gene expression was studied using microarray. Nesfatin-1 immunoreactivity (IR) was abundant in human and rodent beta cells but absent in alpha, delta, PP and ghrelin cells. Importantly, in situ hybridization showed that NUCB2 mRNA is expressed in human and rat islets. Western blot analysis showed that nesfatin-1 IR represented full length NUCB2 in rodent islets. Human islet NUCB2 mRNA was reduced in T2D subjects but upregulated after culture in glucolipotoxic conditions. Furthermore, a positive correlation between NUCB2 and glucagon and insulin gene expression, as well as insulin secretory capacity, was evident. Nesfatin-1 enhanced glucagon secretion but had no effect on insulin secretion from mouse islets or INS-1 (832/13) cells. On the other hand, nesfatin-1 caused a small increase in insulin secretion and reduced glucose during IVGTT in mice. We conclude that nesfatin-1 is a novel glucagon-stimulatory peptide expressed in the beta cell and that its expression is decreased in T2D islets.

Keywords

Regulatory peptide Human islets Rodent islets In situ hybridization Immunochemistry 

Notes

Acknowledgments

Grants support from: Swedish Medical Research Council (Projects No. 522-2008-4216 and K2009-55X 21111-01-4), The Novo Nordisk Foundation, The Royal Physiographic Society in Lund, The Medical Faculty at Lund University, The Gyllenstiernska Krapperup, Fredrik and Ingrid Thuring, Magnus Bergwall, Albert Påhlsson Foundations. Ann-Helen Thorén Fischer, Doris Persson and Britt-Marie Nilsson for excellent technical assistance.

Author contributions

M.R. performed experiments, drew figures and drafted the MS, U.V. performed experiments, M.D.N. performed experiments, analysis and edited the MS, C.L. performed analysis and edited the MS, R.S. performed experiments and drew figures, A.L. performed experiments and drew figures, N.W. conceived the study, performed experiments, drew figures, drafted and edited the MS.

References

  1. Brailoiu GC, Dun SL, Brailoiu E, Inan S, Yang J, Chang JK, Dun NJ (2007) Nesfatin-1: distribution and interaction with a G protein-coupled receptor in the rat brain. Endocrinology 148:5088–5094PubMedCrossRefGoogle Scholar
  2. Foo KS, Brauner H, Ostenson CG, Broberger C (2010) Nucleobindin-2/nesfatin in the endocrine pancreas: distribution and relationship to glycaemic state. J Endocrinol 204:255–263PubMedCrossRefGoogle Scholar
  3. Gonzalez R, Perry RL, Gao X, Gaidhu MP, Tsushima RG, Ceddia RB, Unniappan S (2011a) Nutrient responsive nesfatin-1 regulates energy balance and induces glucose-stimulated insulin secretion in rats. Endocrinology 152:3628–3637CrossRefGoogle Scholar
  4. Gonzalez R, Reingold BK, Gao X, Gaidhu MP, Tsushima RG, Unniappan S (2011b) Nesfatin-1 exerts a direct, glucose-dependent insulinotropic action on mouse islet beta- and MIN6 cells. J Endocrinol 208:R9–R16Google Scholar
  5. Gonzalez R, Tiwari A, Unniappan S (2009) Pancreatic beta cells colocalize insulin and pronesfatin immunoreactivity in rodents. Biochem Biophys Res Commun 381:643–648PubMedCrossRefGoogle Scholar
  6. Gromada J, Franklin I, Wollheim CB (2007) Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr Rev 28:84–116PubMedCrossRefGoogle Scholar
  7. Hohmeier HE, Mulder H, Chen G, Henkel-Rieger R, Prentki M, Newgard CB (2000) Isolation of INS-1-derived cell lines with robust ATP-sensitive K + channel-dependent and -independent glucose-stimulated insulin secretion. Diabetes 49:424–430PubMedCrossRefGoogle Scholar
  8. Iwasaki Y, Nakabayashi H, Kakei M, Shimizu H, Mori M, Yada T (2009) Nesfatin-1 evokes Ca(2+) signaling in isolated vagal afferent neurons via Ca(2+) influx through N-type channels. Biochem Biophys Res Commun 390:958–962PubMedCrossRefGoogle Scholar
  9. Li QC, Wang HY, Chen X, Guan HZ, Jiang ZY (2010) Fasting plasma levels of nesfatin-1 in patients with type 1 and type 2 diabetes mellitus and the nutrient-related fluctuation of nesfatin-1 level in normal humans. Regul Pept 159:72–77Google Scholar
  10. Lyssenko V, Nagorny CL, Erdos MR, Wierup N, Jonsson A, Spegel P, Bugliani M, Saxena R, Fex M, Pulizzi N, Isomaa B, Tuomi T, Nilsson P, Kuusisto J, Tuomilehto J, Boehnke M, Altshuler D, Sundler F, Eriksson JG, Jackson AU, Laakso M, Marchetti P, Watanabe RM, Mulder H, Groop L (2009) Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nat Genet 41:82–88PubMedCrossRefGoogle Scholar
  11. Maejima Y, Sedbazar U, Suyama S, Kohno D, Onaka T, Takano E, Yoshida N, Koike M, Uchiyama Y, Fujiwara K, Yashiro T, Horvath TL, Dietrich MO, Tanaka S, Dezaki K, Oh IS, Hashimoto K, Shimizu H, Nakata M, Mori M, Yada T (2009) Nesfatin-1-regulated oxytocinergic signaling in the paraventricular nucleus causes anorexia through a leptin-independent melanocortin pathway. Cell Metab 10:355–365PubMedCrossRefGoogle Scholar
  12. Mulder H, Lindh AC, Sundler F (1993) Islet amyloid polypeptide gene expression in the endocrine pancreas of the rat: a combined in situ hybridization and immunocytochemical study. Cell Tissue Res 274:467–474PubMedCrossRefGoogle Scholar
  13. Nakata M, Manaka K, Yamamoto S, Mori M, Yada T (2011) Nesfatin-1 enhances glucose-induced insulin secretion by promoting Ca(2+) influx through L-type channels in mouse islet beta-cells. Endocr J (in press)Google Scholar
  14. Oh IS, Shimizu H, Satoh T, Okada S, Adachi S, Inoue K, Eguchi H, Yamamoto M, Imaki T, Hashimoto K, Tsuchiya T, Monden T, Horiguchi K, Yamada M, Mori M (2006) Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 443:709–712CrossRefGoogle Scholar
  15. Pan W, Hsuchou H, Kastin AJ (2007) Nesfatin-1 crosses the blood-brain barrier without saturation. Peptides 28:2223–2228PubMedCrossRefGoogle Scholar
  16. Price TO, Samson WK, Niehoff ML, Banks WA (2007) Permeability of the blood-brain barrier to a novel satiety molecule nesfatin-1. Peptides 28:2372–2381PubMedCrossRefGoogle Scholar
  17. Ramanjaneya M, Chen J, Brown JE, Tripathi G, Hallschmid M, Patel S, Kern W, Hillhouse EW, Lehnert H, Tan BK, Randeva HS (2010) Identification of nesfatin-1 in human and murine adipose tissue: a novel depot-specific adipokine with increased levels in obesity. Endocrinology 151:3169–3180PubMedCrossRefGoogle Scholar
  18. Rosengren AH, Jokubka R, Tojjar D, Granhall C, Hansson O, Li DQ, Nagaraj V, Reinbothe TM, Tuncel J, Eliasson L, Groop L, Rorsman P, Salehi A, Lyssenko V, Luthman H, Renstrom E (2010) Overexpression of alpha2A-adrenergic receptors contributes to type 2 diabetes. Science 327:217–220PubMedCrossRefGoogle Scholar
  19. Shimizu H, Oh IS, Hashimoto K, Nakata M, Yamamoto S, Yoshida N, Eguchi H, Kato I, Inoue K, Satoh T, Okada S, Yamada M, Yada T, Mori M (2009a) Peripheral administration of nesfatin-1 reduces food intake in mice: the leptin-independent mechanism. Endocrinology 150:662–671CrossRefGoogle Scholar
  20. Shimizu H, Oh IS, Okada S, Mori M (2009b) Nesfatin-1: an overview and future clinical application. Endocr J 56:537–543CrossRefGoogle Scholar
  21. Stengel A, Goebel M, Wang L, Tache Y (2010) Ghrelin, des-acyl ghrelin and nesfatin-1 in gastric X/A-like cells: role as regulators of food intake and body weight. Peptides 31:357–369PubMedCrossRefGoogle Scholar
  22. Stengel A, Goebel M, Yakubov I, Wang L, Witcher D, Coskun T, Tache Y, Sachs G, Lambrecht NW (2009) Identification and characterization of nesfatin-1 immunoreactivity in endocrine cell types of the rat gastric oxyntic mucosa. Endocrinology 150:232–238PubMedCrossRefGoogle Scholar
  23. Wierup N, Björkqvist M, Weström B, Pierzynowski S, Sundler F, Sjölund K (2007) Ghrelin and motilin are cosecreted from a prominent endocrine cell population in the small intestine. J Clin Endocrinol Metab 92:3573–3581PubMedCrossRefGoogle Scholar
  24. Wierup N, Richards WG, Bannon AW, Kuhar MJ, Ahren B, Sundler F (2005) CART knock out mice have impaired insulin secretion and glucose intolerance, altered beta cell morphology and increased body weight. Regul Pept 129:203–211PubMedCrossRefGoogle Scholar
  25. Wierup N, Svensson H, Mulder H, Sundler F (2002) The ghrelin cell: a novel developmentally regulated islet cell in the human pancreas. Regul Pept 107:63–69PubMedCrossRefGoogle Scholar
  26. Wierup N, Yang S, McEvilly RJ, Mulder H, Sundler F (2004) Ghrelin is expressed in a novel endocrine cell type in developing rat islets and inhibits insulin secretion from INS-1 (832/13) cells. J Histochem Cytochem 52:301–310PubMedCrossRefGoogle Scholar
  27. Voss U, Riva M, Nitert M, Ling C, Lindqvist A, Wierup N (2010) Nesfatin-1 stimulates insulin secretion, inhibits glucagon secretion and is expressed in human and rodent beta cells. 46th Annual Meeting of the European Association for the Study of Diabetes (EASD), Stockholm, Sweden, Sep 20–24, 2010Google Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Matteo Riva
    • 1
  • Marloes Dekker Nitert
    • 1
  • Ulrikke Voss
    • 1
  • Ramasri Sathanoori
    • 1
  • Andreas Lindqvist
    • 1
  • Charlotte Ling
    • 1
  • Nils Wierup
    • 1
    • 2
    Email author
  1. 1.Department of Clinical SciencesLund University Diabetes CentreMalmöSweden
  2. 2.Department of Clinical Sciences in Malmö, Unit of Neuroendocrine Cell BiologyLund University Diabetes CentreMalmöSweden

Personalised recommendations